Novartis: Carcinoma, Non-Small-Cell Lung trials

The registry lists 102 Carcinoma, Non-Small-Cell Lung studies with Novartis as lead sponsor. 8 are open to participants now and 39 have results posted.

Phase 1 44Phase 2 40Phase 3 16Phase 4 3No phase 9(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid TumorsRecruitingNCT07801508Phase 1
• Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid TumorsRecruitingNCT07660055Phase 1
• Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid TumorsRecruitingNCT07630961Phase 1
• Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsRecruitingNCT07261631Phase 1
• A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung CancersRecruitingNCT07117214Phase 1
• Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal CancersRecruitingNCT06562192Phase 1
• A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South KoreaRecruitingNCT05703516
• Dabrafenib and/or Trametinib Rollover StudyRecruitingNCT03340506Phase 4
• Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.CompletedNCT05110196Phase 4Results posted
• Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLCTerminatedNCT04926831Phase 2Results posted
• Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line TherapyTerminatedNCT04816214Phase 3Results posted
• Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationCompletedNCT04677595Phase 2Results posted
• A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLCCompletedNCT04452877Phase 2Results posted
• Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping MutationTerminatedNCT04427072Phase 3Results posted
• Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping MutationsTerminatedNCT04323436Phase 2Results posted
• Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%TerminatedNCT04139317Phase 2Results posted
• This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.TerminatedNCT03968419Phase 2Results posted
• [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)TerminatedNCT03724253Phase 2Results posted
• Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung CancerCompletedNCT03647488Phase 2Results posted
• Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC SubjectsTerminatedNCT03631199Phase 3Results posted
• Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line TherapyTerminatedNCT03626545Phase 3Results posted
• Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-ATerminatedNCT03447769Phase 3Results posted
• A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin LymphomaTerminatedNCT03207867Phase 2Results posted
• A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.TerminatedNCT02711345Phase 1Results posted
• Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced MalignanciesTerminatedNCT02608268Phase 1/2Results posted
• Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.CompletedNCT02460224Phase 1/2Results posted
• LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.CompletedNCT02450903Phase 2Results posted
• Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)CompletedNCT02414139Phase 2Results posted
• Phase I/II Study of PDR001 in Patients With Advanced MalignanciesCompletedNCT02404441Phase 1/2Results posted
• A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to LeptomeningesCompletedNCT02336451Phase 2Results posted
• Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.TerminatedNCT02335944Phase 1/2Results posted
• Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung CancerTerminatedNCT02323126Phase 2Results posted
• A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid MalignanciesCompletedNCT02108964Phase 1/2Results posted
• LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With CrizotinibCompletedNCT02040870Phase 1/2Results posted
• Dovitinib for Patients With Tumor Pathway Activations Inhibited by DovitinibCompletedNCT01831726Phase 2Results posted
• LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and CrizotinibCompletedNCT01828112Phase 3Results posted
• LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung CancerCompletedNCT01828099Phase 3Results posted
• LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung CancerCompletedNCT01685138Phase 2Results posted
• LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and CrizotinibCompletedNCT01685060Phase 2Results posted
• An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR MutationsTerminatedNCT01646125Phase 2Results posted
• A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi TreatmentCompletedNCT01610336Phase 2Results posted
• Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.CompletedNCT01336634Phase 2Results posted
• Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung CancerCompletedNCT01297491Phase 2Results posted
• A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma KinaseCompletedNCT01283516Phase 1Results posted
• A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.CompletedNCT01124864Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)CompletedNCT00172042Phase 3Results posted
• Dose Escalating Study of the Safety and Efficacy of Patupilone, q3w, in Patients With Non-small Cell Lung CancerCompletedNCT00171834Phase 1/2Results posted
• Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study TreatmentsActive, not recruitingNCT07468071Phase 1/2
• Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United StatesCompletedNCT06161051
• A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)CompletedNCT06159790Phase 3
• Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring METex14 MutationsCompletedNCT05796726
• Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.WithdrawnNCT05791097Phase 3
• Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With CapmatinibCompletedNCT05675683
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
• A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid TumorsTerminatedNCT05462873Phase 1
• Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationTerminatedNCT05358249Phase 1/2
• Study of MGY825 in Patients With Advanced Non-small Cell Lung CancerTerminatedNCT05275868Phase 1
• Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerTerminatedNCT05132075Phase 3
• Managed Access Programs for LDK378, CeritinibNo longer availableNCT05100134
• Managed Access Programs for INC280, CapmatinibNo longer availableNCT04741789
• Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationActive, not recruitingNCT04699188Phase 1/2
• Special Drug Use-results Surveillance of Tabrecta TabletsCompletedNCT04575025
• Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung CancerNo longer availableNCT04507919
• A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain MetastasesWithdrawnNCT04460729Phase 2
• A Phase I/Ib Study of NIZ985 Alone and in Combination With SpartalizumabTerminatedNCT04261439Phase 1
• Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected MalignanciesTerminatedNCT04000529Phase 1
• Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.Active, not recruitingNCT03891953Phase 1
• A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.TerminatedNCT03549000Phase 1
• Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating MutationsWithdrawnNCT03529084Phase 3
• Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCActive, not recruitingNCT03333343Phase 1
• Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)WithdrawnNCT03240393Phase 2
• PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC PatientsTerminatedNCT03064854Phase 1
• Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment AloneActive, not recruitingNCT03040973Phase 2
• A Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaTerminatedNCT02974725Phase 1
• A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
• A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatCompletedNCT02890069Phase 1
• Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLCWithdrawnNCT02672358Phase 2
• A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET AmplificationTerminatedNCT02468661Phase 1
• Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung CancerActive, not recruitingNCT02393625Phase 1
• Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT02299505Phase 1
• Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.CompletedNCT02292550Phase 1
• Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid TumorsCompletedNCT01999738Phase 1
• Expanded Treatment Protocol With LDK378 in ALK(+) NSCLCNo longer availableNCT01947608
• Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung CancerCompletedNCT01772797Phase 1
• A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid TumorsCompletedNCT01626209Phase 1
• Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung CancerCompletedNCT01577654Phase 2
• Study of INC280 in Patients With c-MET Dependent Advanced Solid TumorsCompletedNCT01324479Phase 1
• Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)CompletedNCT01002924Phase 2
• A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung CancerTerminatedNCT00738387Phase 3
• An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00674102Phase 1
• ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung CancerTerminatedNCT00662597Phase 3
• Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural MesotheliomaCompletedNCT00535951Phase 1
• Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)CompletedNCT00511485Phase 2
• Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) PatientsCompletedNCT00457119Phase 1
• Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With ChemotherapyCompletedNCT00456833Phase 1
• Safety of Everolimus and Pemetrexed in Lung Cancer PatientsCompletedNCT00434174Phase 1
• Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung CancerCompletedNCT00219297Phase 2
• Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT00124280Phase 2
• Non-small Cell Lung Cancer RegistryCompletedNCT00099541Phase 4
• Non-small Cell Lung Cancer Study US75 (Z-PACT)CompletedNCT00086268Phase 3